Worth reading
19Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateKey initiatives
01Realization of the “Drug Discovery AI Factory” concept
02Early implementation in society of the first natural-language AI medical device in Japan and the United States
03FRONTEO co-creation drug discovery ecosystem concept
04Comprehensive co-creation model
05DDAIF Innovation Bridge
Plan assumptionsIncreasing numbers of chronic disease patients due to global population aging, Growing interest in personalized and precision medicine, The global drug discovery support services market is forecast to reach $31.4 billion (approximately ¥4.7 trillion) in 2026, The AI medical device market is expected to expand approximately sixfold over the next 5 years (company forecast)
Size of the Target MarketMarket Global drug discovery support services market / Scale 2026: $31.4 billion (approximately ¥4.7 trillion) / Growth rate Not disclosed / Source Prepared based on Global Information’s “Global Drug Discovery Services Market: Future Forecast by Process (Target Selection, Validation, Lead Generation), Type (Chemistry, Biology), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology), End User (Pharmaceutical, Biotechnology), and Region, through 2026”, Market Target discovery and validation processes / Scale 2021: ¥610 billion; 2026: ¥1.062 trillion / Growth rate CAGR 11.3％、CAGR 12.4％ / Source Prepared based on materials from Global Information, Market Domestic AI systems market for diagnosis and clinical support / Scale Approximately sixfold growth over the next 5 years / Growth rate Not disclosed / Source Company forecast
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Progress against the plan | Annual update |
| Plan assumptions | Increasing numbers of chronic disease patients due to global population aging, Growing interest in personalized and precision medicine, The global drug discovery support services market is forecast to reach $31.4 billion (approximately ¥4.7 trillion) in 2026, The AI medical device market is expected to expand approximately sixfold over the next 5 years (company forecast) |
| Key initiatives | Realization of the “Drug Discovery AI Factory” concept, Early implementation in society of the first natural-language AI medical device in Japan and the United States, FRONTEO co-creation drug discovery ecosystem concept, Comprehensive co-creation model, DDAIF Innovation Bridge |
| Size of the Target Market | Market Global drug discovery support services market / Scale 2026: $31.4 billion (approximately ¥4.7 trillion) / Growth rate Not disclosed / Source Prepared based on Global Information’s “Global Drug Discovery Services Market: Future Forecast by Process (Target Selection, Validation, Lead Generation), Type (Chemistry, Biology), Drug Type (Small Molecules, Biologics), Therapeutic Area (Oncology, Neurology), End User (Pharmaceutical, Biotechnology), and Region, through 2026”, Market Target discovery and validation processes / Scale 2021: ¥610 billion; 2026: ¥1.062 trillion / Growth rate CAGR 11.3％、CAGR 12.4％ / Source Prepared based on materials from Global Information, Market Domestic AI systems market for diagnosis and clinical support / Scale Approximately sixfold growth over the next 5 years / Growth rate Not disclosed / Source Company forecast |
| Publication date | 30 June 2026 |
Items this document does not state (19)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.FRONTEO explained that it is developing drug discovery and medical device businesses using KIBIT against a backdrop of rising numbers of chronic disease patients due to global population aging, growing interest in personalized and precision medicine, and increasing difficulty and costs in pharmaceutical research and development. It also cited addressing social issues such as legal violations and economic security as a business driver.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.